INTELLIGENT BIO SOLUTIONS INC.

false 0001725430 0001725430 2026-07-31 2026-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2026 INTELLIGENT BIO SOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-39825 82-1512711 (State of Incorporation) (Commission File Number) (IRS Employer Identification No.) 135 West 41st Street , 5th Floor New York , NY 10036 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (646) 790-5756 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value INBS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. As a result of (a) the sale of shares of common stock by Intelligent Bio Solutions Inc. (the “Company”) pursuant to the previously disclosed At The Market Offering Agreement, dated September 18, 2024, between the Company and Ladenburg Thalmann & Co. Inc.; (b) the exercise of previously disclosed outstanding warrants to purchase common stock; and (c) the issuance of shares of restricted common stock pursuant to the previously disclosed Investor Relations and Corporate Development Advisory Agreement, dated February 29, 2024, between the Company and ClearThink Capital Partners LLC, the total number of outstanding shares of the Company’s common stock as of the close of business on July 31, 2026, is 3,018,188 shares. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 3, 2026 INTELLIGENT BIO SOLUTIONS INC. By: /s/ Spiro Sakiris Name: Spiro Sakiris Title: Chief Financial Officer